Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
ACET Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Adicet Bio, Inc.NASDAQ: ACET
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.08M fell 42.3% year over year, behind the -29.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $3.62M (-84.2%) for the fiscal year ending Dec 2026, a slowdown from the -18.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.08M-40.4% QoQ
- Last fiscal yearDec 2025
- $22.99M-18.8% YoY
- LTMMar 2026
- $20M-29.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 22.99M USD
- Year-over-year change
- -18.8%
- 4-year CAGR
- +0.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.99M | -18.8% |
| FY2024 | 2024-12-31 | 28.29M | +6.6% |
| FY2023 | 2023-12-31 | 26.53M | +0.9% |
| FY2022 | 2022-12-31 | 26.3M | +18.3% |
| FY2021 | 2021-12-31 | 22.22M | — |
Selling, General & Admin vs competitors
How ACET compares with its peers on the latest reported figures
- ACET's LTM Mar 2026 selling, general & admin of $20M is the 4th highest of the 8 companies compared; the peer median is $19.35M.
- Its year-over-year change of -29.6% is the lowest of 7, against a peer median of +2.0%.
- Over three fiscal years its annual growth of -4.4% compares with a peer median of -3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $30.56M | -0.6% | +16.3% | 334.5% | |
| LTM Mar 2026 | $23.53M | +30.1% | +11.7% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $22.61M | -10.5% | +40.4% | — |
| LTM Mar 2026 | $20M | -29.6% | -4.4% | — | |
| LTM Jun 2026 | $19.35M | +4.7% | -9.7% | 92.1% | |
| LTM Mar 2026 | $13.76M | +12.8% | -21.8% | 600.0% | |
| LTM Mar 2026 | $8.98M | -8.4% | -3.8% | — | |
| LTM Jun 2024 | $7.81M | — | -15.8% | 957.8% | |
| Peer median (excluding ACET) | $19.35M | +2.0% | -3.8% | 467.3% | |
Competitors are the stored peer set for ACET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.73M | 24.99M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 6.38M |
| Gross Profit | 9.73M | 24.99M | 0 | 0 | (6.38M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 48.94M | 71.25M | 106.04M | 99.32M | 99.13M |
| Selling, General & Admin | 22.22M | 26.3M | 26.53M | 28.29M | 22.99M |
| Operating Expenses | 71.16M | 97.54M | 152.04M | 127.62M | 115.73M |
| Depreciation & Amortization | 1.54M | 5.01M | 6.1M | 6.47M | 6.38M |
| EBITDA | (60.41M) | (64.7M) | (136.54M) | (110.65M) | (110.39M) |
| EBITDA Margin | -620.9% | -258.9% | — | — | — |
| Operating Income | (61.43M) | (72.55M) | (152.04M) | (127.62M) | (122.11M) |
| Operating Margin | -631.4% | -290.3% | — | — | — |
| Interest Income | 91K | 3.76M | 9.98M | 10.71M | 5.78M |
| Interest Expense | 176K | 80K | 25K | 4K | 36K |
| Other Income / Expenses | (691K) | 2.76M | 9.38M | 10.49M | 5.31M |
| Income Before Tax | (62.12M) | (69.79M) | (142.66M) | (117.12M) | (116.8M) |
| Pre-Tax Margin | -638.5% | -279.3% | — | — | — |
| Income Tax Expense | (125K) | 0 | 0 | 0 | 0 |
| Net Income | (62M) | (69.79M) | (142.66M) | (117.12M) | (116.8M) |
| Net Margin | -637.2% | -279.3% | — | — | — |
| EPS (Basic) | (32.00) | (27.20) | (52.96) | (21.28) | (16.95) |
| EPS (Diluted) | (32.00) | (27.20) | (52.96) | (21.28) | (16.95) |
| Weighted Avg Shares | 1.93M | 2.57M | 2.69M | 5.49M | 6.89M |
| Weighted Avg Shares (Diluted) | 1.93M | 2.57M | 2.69M | 5.49M | 6.89M |
Adicet Bio, Inc.
NASDAQ:ACET
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.